Quantitative, spatial resolution of the epigenetic field effect in prostate cancer

Prostate

Volumn 68, Issue 2, 2008, Pages 152-160

  Mehrotra, Jyoti ^a   Varde, Shobha ^a   Wang, Haiying ^a   Chiu, Hsiling ^a   Vargo, Janet ^a   Gray, Karen ^a   Nagle, Raymond B ^b   Neri, Jaclyn R ^b   Mazumder, Abhijit ^a,c  

^a JOHNSON AND JOHNSON   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c NONE   (United States)

Author keywords

Field effect; GSTP1; Methylation

Indexed keywords

BISULFITE;

APC GENE; ARTICLE; BIOPSY; CANCER RECURRENCE; CARCINOGENESIS; CELL TRANSFORMATION; CONTROLLED STUDY; CORE BIOPSY; EPIGENETICS; EX VIVO STUDY; FIELD EFFECT; GENE; GENE SEQUENCE; GSTP1 GENE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; METHYLATION; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; QUANTITATIVE ANALYSIS; RARBETA2 GENE; RASSF1A GENE; SEQUENCE ANALYSIS; TUMOR VOLUME;

ADENOMATOUS POLYPOSIS COLI PROTEIN; BASE SEQUENCE; BIOPSY; DNA METHYLATION; DNA, NEOPLASM; EPIGENESIS, GENETIC; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PROSTATIC NEOPLASMS; RECEPTORS, RETINOIC ACID; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 38749108119     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20675     Document Type: Article

References (21)

1. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953;6:963-968.
2. Suzuki H, Watkins DN, Jair K-W, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, Toyota M, Tokino T, Hinoda Y, Imai K, Herman JG, Baylin SB. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genetics 2004;36:417-422.
3. Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR, Einspahr JG, Buckmeier J, Alberts DS, Hamilton SR, Issa JP. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005;97:1330-1338.
4. Endoh M, Tamura G, Honda T, Homma N, Terashima M, Nishizuka S, Motoyama T. RASSF2, a potential tumor suppressor, is silenced by CpG island hypermethylation in gastric cancer. Br J Cancer 2005;93:1395-1399.
5. Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Lange J, Lapides A, Garrett E, Argani P, Sukumar S. Quantitative multiplex-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 2004;64:4442-4452.
6. Yan PS, Venkataramu C, Ibrahim A, Liu JC, Shen RZ, Diaz NM, Centeno B, Weber F, Leu YW, Shapiro CL, Eng C, Yeatman TJ, Huang TH. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 2006;12:6626-6636.
7. Guo M, House MG, Hooker C, Han Y, Heath E, Gabrielson E, Yang SC, Baylin SB, Herman JG, Brock MV. Promoter hypermethylation of resected bronchial margins: A field defect of changes? Clin Cancer Res 2004;10:5131-5136.
8. Dammann R, Strunnikova M, Schagdarsurengin U, Rastetter M, Papritz M, Hattenhorst UE, Hofmann HS, Silber RE, Burdach S, Hansen G. CpG island methylation and expression of tumor-associated genes in lung carcinoma. Eur J Cancer 2005;41:1223-1236.
9. Krop I, Player A, Tablante A, Taylor-Parker M, Lahti-Domenici J, Fukuoka J, Batra SK, Papadopoulos N, Richards WG, Sugarbaker DJ, Wright RL, Shim J, Stamey TA, Sellers WR, Loda M, Meyerson M, Hruban R, Jen J, Polyak K. Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. Mol Cancer Res 2004;2:489-494.
10. Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, Emmert-Buck MR, Tangrea JA, Libutti SK, Linehan WM, Woodson KG. Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst 2006;98:255-261.
11. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A 1994;91:11733-11737.
12. Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, Epstein JI, Partin AW, Sidransky D. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 2005;11:8321-8325.
13. Jeronimo C, Henrique R, Hoque MO, Ribeiro FR, Oliveira J, Fonseca D, Teixeira MR, Lopes C, Sidransky D. Quantitative RARbeta2 hypermethylation: A promising prostate cancer marker. Clin Cancer Res 2004a;10:4010-4014.
14. Jeronimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, Oliveira J, Teixeira MR, Lopes C, Sidransky D. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004b;10:8472-8478.
15. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004;64:1975-1986.
16. Henrique R, Jeronimo C, Teixeira MR, Hoque MO, Carvalho AL, Pais I, Ribeiro FR, Oliveira J, Lopes C, Sidransky D. Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: Clues for clonal progression in prostate carcinogenesis. Mol Cancer Res 2006;4:1-8.
17. Woodson K, Gillespie J, Hanson J, Emmert-Buck M, Phillips JM, Linehan WM, Tangrea JA. Heterogeneous gene methylation patterns among pre-invasive and cancerous lesions of the prostate: A histopathologic study of whole mount prostate specimens. Prostate 2004;60:25-31.
18. Aitchison A, Warren A, Neal D, Rabbitts P. RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues. Prostate 2007;67:638-644.
19. Villers A, McNeal JE, Freiha JS, Stamey TA. Multiple cancers in the prostate. Cancer 1992;70:2313-2318.
20. Braakhuis BJM, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: Evidence and clinical implications. Cancer Res 2003;63:1727-1730.
21. Bastian PJ, Ellinger J, Heukamp LC, Kahl P, Müller SC, von Rücker A. Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol 2007;51:665-674.